FIREHAWK, safety and effectiveness approved by early clinical studies


SAN FRANCISCO, CALIF.--Early studies provide evidence that the FIREHAWK bioabsorbable polymer sirolimus-eluting stent is safe and effective in CAD patients.
Run-Lin Gao, MD, of Fu Wai Hospital and National Center for Cardiovascular Diseases of China, presented an update of the 4- and 13-month results from the FIREHAWK First-in-Man Study, which assessed the preliminary safety and feasibility of the new-generation DES system (MicroPort). The prospective, single-center pilot study included adult patients with de novo, single lesions in native coronary arteries.
FIREHAWK is a targeted-release abluminal groove filled bioabsorbable polymer SES developed by MicroPort.In the study, the device success rate was 95.7% and lesion and clinical success rates were both 100%.Overall, there was zero incidence of MACE — the primary endpoint of the study — during the 13-month follow-up period. One patient died 5 days after the index procedure due to hemorrhagic stroke, Gao said. Only one target vessel revascularization occurred in a non-target lesion. There was no evidence of thrombosis.
Angiographic follow-up showed that the average in-stent late lumen loss was 0.13 mm at 4 months and 0.16 mm at 13 months. Four-month optimal coherence tomography was performed in 14 of 17 eligible patients, for which the researchers analyzed 14 stented segments every 0.3 mm for 11,551 struts. Results showed that 96.2% were fully covered; of the remaining 3.8%, only 0.1% weremalapposed.
"The preliminary safety and feasibility of the FIREHAWK sirolimus-eluting stent has been confirmed by clinical, angiographic and OCT follow-up," Gao said. "With these promising data, a pivotal randomized trial has been initiated." Gao provided an update on the TARGET Clinical Program, which includes the premarket clinical trials of the FIREHAWK First-in-Man Study, TARGET I trial and TARGET II Registry, all of which involve the FIREHAWK stent.
The program will enroll 995 patients. As of May 2011, researchers have enrolled 510 implant cases in TARGET I, which will compare FIREHAWK and Xience V. The primary clinical endpoint ofTARGET II is the device-oriented composite of cardiac death, target vessel MI or ischemia-driven target lesion revascularization at 1 year. More than 30 clinical centers in China will be involved in the program.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs MicroPort Scientific Corporation
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6957